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 Dear Editor, 
 
The CRESCENDO trial of rimonabant1 confirmed the conclusions of previous meta-
analyses: rimonabant increases the risk of serious adverse events with no evidence of 
benefit on major cardiovascular outcomes.2-4 According to Topol et al., the trial has 
been stopped prematurely because the level of serious neuropsychiatric effects was 
deemed unacceptable by regulatory authorities.1 We argue that the trial was 
terminated too late, not too early. First, CRESCENDO began months after the 
marketing approval (MA) for rimonabant as a weight-loss drug had been requested in 
Europe. Testing the efficacy of a drug on hard outcomes after its marketing for 
uncertain surrogates is a time sequence in the interest of the manufacturer, not of 
public health. Second, the MA for rimonabant was issued by the EC in June 2006, but 
withdrawn in November 2008.5 However, concerns about an unfavorable benefit-risk 
balance of rimonabant had already been expressed in 2006, shortly after the MA.3 
Rimonabant was never marketed in the USA as the application was rejected by the 
FDA in 20074 (figure). Thus the European Medicines Agency was indeed rather slow 
in cancelling the MA, and when it did so, it was on the basis of strong evidence and 
not of concerns as suggested by Topol et al. Last but not least, there is no evidence 
that a longer duration of CRESCENDO would have demonstrated rimonabant’s 
benefits. Even with 12190 and 5092 participants at year1 and year2, respectively, not 
the slightest divergence in survival curves between arms could be detected, a sharp 
contrast with the absolute 10.9% difference in psychiatric disorders.1  
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Figure 1. Timeline of main procedural steps and available scientific information 
relative to rimonabant as a weight-loss drug. 
CHMP: EMEA’s Committee for Medicinal Product of Human Use, EC: European 
Commission, EMEA: European Medicines Agency, FDA: Food and Drug 
Administration, MA: Marketing Authorization, SPC: Summary of Product 
Characteristics 
 
